Behavioral Scientist Dr. Kristina Curtis joins Jörn Schattenberg, Louise Campbell and Roger Green to discuss highlights of the Global Think Tank on SLD. This conversation focuses on the program’s history and different ideas on behavioral interventions.
This episode includes a discussion on patient management and self-management from the Global Think-Thank on Steatotic Liver Disease plus a segment from April’s Drug Development roundtable focusing on NITs in clinical trials. This week’s Newsmaker is Jose Willemse, President of the Dutch Liver Patients Association.
On the first anniversary of Stephen Harrison’s passing, we take an episode to remember our co-founder and colleague, Stephen Harrison, his contributions to MASH and how his legacy moves forward.
This week’s expert, hepatologist and Key Opinion Leader Scott Friedman, discusses the increasing acceptance of gene therapy in liver disease, evolving knowledge about the diversity of stellate cells and other advances in basic liver science. He closes with a request that all listeners do whatever we can to support NIH funding of science.
This week’s Newsmaker is hepatologist and key opinion leader Naga Chalasani of Indiana University. He discusses a recent article his group published in Hepatology Communications titled Early Experience with Resmetirom To Treat Metabolic-Associated Steatohepatitis with Fibrosis in a Real-World Setting.
The opening portion of SurfingMASH’s April roundtable on drug development looks at developments in the FGF-21 mode of action and, more generally, treatment of patients with cirrhosis, with tremendous enthusiasm.
SurfingMASH kicks off a month of Drug Development stories looking at FGF-21s and the future of therapies for cirrhosis and MASH, plus a paper on real-world resmetirom prescribing.
This week’s expert, hepatologist and Key Opinion Leader Mazen Noureddin, discusses exciting advances in MASH and cirrhosis drug development for multiple modes of action.
This week’s Newsmaker is Mike Betel, Founder of the Fatty Liver Alliance. He discusses some of the reasons that key MASLD Patient Advocates like himself are getting more visibility at a broader swath of global conferences and the messages he delivers at the conferences he attends.
This concluding segment of the Emerging Trends Conference 2025 Roundtable expresses optimism about the future for Steatotic Liver Disease patients, with a better understanding of how to treat based on viewing steatotic liver disease as a spectrum and an accompanying explosion of the number and diversity of drugs available to treat patients with MASLD, MetALD and ALD.
